In the SR “Anti-vascular endothelial growth factor for proliferative diabetic retinopathy”, the authors concluded that there was low or very low quality of evidence regarding the safety and efficacy of the use of anti-VEGFs in relation to proliferative diabetic retinopathy. This evidence concerns the gene VEGFA and proliferative diabetic retinopathy.